Accuracy of administrative claims prescription fill data to estimate glucocorticoid use and dose in patients with rheumatoid arthritis

Author:

Galvao Rachel W.12,Curtis Jeffrey R.3,Harrold Leslie R.45,Wu Qufei6,Xie Fenglong3ORCID,George Michael D.2

Affiliation:

1. Department of Internal Medicine Yale University New Haven Connecticut USA

2. Division of Rheumatology University of Pennsylvania Philadelphia Pennsylvania USA

3. Division of Clinical Immunology and Rheumatology University of Alabama at Birmingham Birmingham Alabama USA

4. CorEvitas Waltham Massachusetts USA

5. Division of Rheumatology University of Massachusetts Medical School Worcester Massachusetts USA

6. Center for Clinical Epidemiology and Biostatistics University of Pennsylvania Philadelphia Pennsylvania USA

Abstract

AbstractPurposeTo assess accuracy of administrative claims prescription fill‐based estimates of glucocorticoid use and dose, and approximate bias from glucocorticoid exposure misclassification.MethodsWe identified adults with rheumatoid arthritis with linked Medicare and CorEvitas registry data. An algorithm identifying glucocorticoid use and average dose over 90 days from Medicare prescription fills was compared to physician‐reported measures from a CorEvitas visit during the same period, using weighted kappa to compare doses (none, ≤5 mg, 5–10 mg, >10 mg/day). A deterministic sensitivity analysis examined the effect of exposure misclassification on estimated glucocorticoid‐associated infection risk from a prior study.ResultsWe identified 621 observations among 494 patients. Prescription fills identified glucocorticoid use in 41.9% of observations versus 31.1% identified by CorEvitas physician‐report. For glucocorticoid use (yes/no), prescription fills had sensitivity 88.1% (95% CI 82.7–92.3), specificity 79.0% (74.8–82.7), PPV 65.4% (59.3–71.2), NPV 93.6% (90.6–95.9), and 81.8% agreement with CorEvitas, with kappa 0.61 (moderate to substantial agreement). There was 89.5% agreement between prescription fills and physician‐reported doses, with weighted kappa 0.56 (moderate agreement). Applying these results to a prior Medicare study evaluating glucocorticoid‐associated infection risk [risk ratio 1.44 (95% CI 1.41–1.48)] led to an externally adjusted risk ratio of 1.74 when accounting for exposure misclassification, representing −17% bias in infection risk estimate.ConclusionsThis study supports the use of claims data to estimate glucocorticoid use and dose, but investigators should account for exposure misclassification, which may lead to underestimates of glucocorticoid risks. Our results could be applied to adjust risk estimates in other studies that use prescription fills to estimate glucocorticoid use.

Funder

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3